{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 33,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/7",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.52,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Male Mouse Brain PK Comparison Cipro vs. Combo",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9ee25c0-93bd-4515-a2bf-fc2324349c21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.245
      },
      "kind": "diagram",
      "text": "Synergistic Mode of Action diagram showing Cipro diffusion and efflux blocking by Celecoxib",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f1b9516-1ced-4cf8-ab9c-221bd8ce0379",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.06,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "This finding is attributed to Celecoxib blocking exit of Ciprofloxacin in the neuron",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f1b29d6-b40c-4281-8b5f-135790c83aca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.52,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "PrimeC's combination (Celecoxib + Ciprofloxacin) remained at a higher concentration in rodent brain tissue for longer, when compared to administration of Ciprofloxacin alone",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10da486-24d6-4061-8ee3-c12362223517",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Synergistic Benefit: In-Vitro & In-Vivo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dc9ee11-69d0-49ba-af58-88da394f0b0b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}